Repligen Reports Fourth Quarter and Full Year 2018 Financial Results
Record quarterly revenue of $51.9 million represents 25% year-over-year growth, and record annual revenue of $194.0 million represents 37% year-over-year growth Overall organic revenue growth was 25% for the fourth quarter and 17% for the year 2018 WALTHAM, Mass., Feb. 21, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter and full year 2018. Provided in this press release are financial highlights for the three- and twelve-month periods ended December 31, 2018, followed by our current financial guidance for the year 2019, and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer, said, “We are delighted with the way we closed out 2018 with both revenues and orders accelerating in the second half of the year and overall organic growth coming in at 17% for the year and 25% for the fourth
